For the readers interested in the stock health of BioLineRx Ltd. (BLRX). It is currently valued at $1.02. When the transactions were called off in the previous session, Stock hit the highs of $1.10, after setting-off with the price of $1.07. Company’s stock value dipped to $1.01 during the trading on the day. When the trading was stopped its value was $1.54.Recently in News on September 19, 2022, BioLineRx Announces $15 Million Registered Direct Offering. BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 13,636,365 of the Company’s American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 13,636,365 ADSs, at a combined purchase price of $1.10 per ADS and associated warrant. Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx. The offering is expected to close on or about September 21, 2022, subject to satisfaction of customary closing conditions. You can read further details here
BioLineRx Ltd. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.1900 on 01/18/22, with the lowest value was $1.0100 for the same time period, recorded on 09/19/22.
BioLineRx Ltd. (BLRX) full year performance was -61.80%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, BioLineRx Ltd. shares are logging -67.62% during the 52-week period from high price, and 0.99% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.01 and $3.15.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3143075 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the BioLineRx Ltd. (BLRX) recorded performance in the market was -50.00%, having the revenues showcasing -21.54% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 49.41M, as it employees total of 38 workers.
BioLineRx Ltd. (BLRX) in the eye of market guru’s
During the last month, 0 analysts gave the BioLineRx Ltd. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 1.4234, with a change in the price was noted -0.38. In a similar fashion, BioLineRx Ltd. posted a movement of -27.14% for the period of last 100 days, recording 189,311 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BLRX is recording 0.03 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.03.
BioLineRx Ltd. (BLRX): Stocks Technical analysis and Trends
Raw Stochastic average of BioLineRx Ltd. in the period of last 50 days is set at 1.03%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 1.23%. In the last 20 days, the company’s Stochastic %K was 24.58% and its Stochastic %D was recorded 32.75%.
If we look into the earlier routines of BioLineRx Ltd., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -50.00%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -33.33%, alongside a downfall of -61.80% for the period of the last 12 months. The shares increased approximately by -37.80% in the 7-day charts and went up by -39.64% in the period of the last 30 days. Common stock shares were lifted by -21.54% during last recorded quarter.